142 related articles for article (PubMed ID: 10556200)
21. Immunohistochemical analysis of Fas ligand expression in sarcomas. Sarcomas express high level of FasL in vivo.
Lee SH; Jang JJ; Lee JY; Kim SY; Park WS; Kim CS; Kim SH; Yoo NJ
APMIS; 1998 Nov; 106(11):1035-40. PubMed ID: 9890264
[TBL] [Abstract][Full Text] [Related]
22. Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict.
O'Connell J; Bennett MW; Nally K; Houston A; O'Sullivan GC; Shanahan F
Ann N Y Acad Sci; 2000 Jun; 910():178-92; discussion 193-5. PubMed ID: 10911913
[TBL] [Abstract][Full Text] [Related]
23. Prevalence and clinical significance of resistance to perforin- and FAS-mediated cell death in leukemia.
Otten HG; van Ginkel WG; Hagenbeek A; Petersen EJ
Leukemia; 2004 Aug; 18(8):1401-5. PubMed ID: 15215873
[TBL] [Abstract][Full Text] [Related]
24. Expression of Fas ligand is not a main mechanism used by tumors to counteract antitumor immunity.
Chen CM; Song W; Kao JY; Zheng QD; Chen JJ
Front Biosci; 2004 Jan; 9():448-56. PubMed ID: 14766381
[TBL] [Abstract][Full Text] [Related]
25. [CD95 resistance and Fas ligand synthesis as mechanism of defense by immunocompetent cells in pancreatic tumors].
Ungefroren H; Voss M; Henne-Bruns D; Kremer B; Kalthoff H
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):63-7. PubMed ID: 14518214
[TBL] [Abstract][Full Text] [Related]
26. Involvement of Fas-Fas ligand interactions in graft rejection.
Martinez OM; Krams SM
Int Rev Immunol; 1999; 18(5-6):527-46. PubMed ID: 10672500
[TBL] [Abstract][Full Text] [Related]
27. Regulation of fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen.
Mor G; Kohen F; Garcia-Velasco J; Nilsen J; Brown W; Song J; Naftolin F
J Steroid Biochem Mol Biol; 2000; 73(5):185-94. PubMed ID: 11070347
[TBL] [Abstract][Full Text] [Related]
28. Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response.
Sata M; Perlman H; Muruve DA; Silver M; Ikebe M; Libermann TA; Oettgen P; Walsh K
Proc Natl Acad Sci U S A; 1998 Feb; 95(3):1213-7. PubMed ID: 9448311
[TBL] [Abstract][Full Text] [Related]
29. The resolution of lesions induced by Leishmania major in mice requires a functional Fas (APO-1, CD95) pathway of cytotoxicity.
Conceição-Silva F; Hahne M; Schröter M; Louis J; Tschopp J
Eur J Immunol; 1998 Jan; 28(1):237-45. PubMed ID: 9485203
[TBL] [Abstract][Full Text] [Related]
30. Cells behaving badly: a theoretical model for the Fas/FasL system in tumour immunology.
Webb SD; Sherratt JA; Fish RG
Math Biosci; 2002; 179(2):113-29. PubMed ID: 12208611
[TBL] [Abstract][Full Text] [Related]
31. IL-4 diminishes perforin-mediated and increases Fas ligand-mediated cytotoxicity In vivo.
Aung S; Graham BS
J Immunol; 2000 Apr; 164(7):3487-93. PubMed ID: 10725701
[TBL] [Abstract][Full Text] [Related]
32. Fas ligand-dependent suppression of autoimmunity via recruitment and subsequent termination of activated T cells.
Modiano JF; Sun J; Lang J; Vacano G; Patterson D; Chan D; Franzusoff A; Gianani R; Meech SJ; Duke R; Bellgrau D
Clin Immunol; 2004 Jul; 112(1):54-65. PubMed ID: 15207782
[TBL] [Abstract][Full Text] [Related]
33. Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3(+) large granular lymphocyte leukemia.
Lamy T; Liu JH; Landowski TH; Dalton WS; Loughran TP
Blood; 1998 Dec; 92(12):4771-7. PubMed ID: 9845544
[TBL] [Abstract][Full Text] [Related]
34. Molecular and cellular mechanisms regulating T and B cell apoptosis through Fas/FasL interaction.
Ju ST; Matsui K; Ozdemirli M
Int Rev Immunol; 1999; 18(5-6):485-513. PubMed ID: 10672498
[TBL] [Abstract][Full Text] [Related]
35. Induction of Fas ligand (CD95L) by the toxic mistletoe lectins in human lymphocytes.
Büssing A; Stein GM; Pfüller U; Schietzel M
Anticancer Res; 1999; 19(3A):1785-90. PubMed ID: 10470116
[TBL] [Abstract][Full Text] [Related]
36. T cell-tumor cell: a fatal interaction?
Chappell DB; Restifo NP
Cancer Immunol Immunother; 1998 Oct; 47(2):65-71. PubMed ID: 9769114
[TBL] [Abstract][Full Text] [Related]
37. Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: a lethal two-way street.
Zeytun A; Hassuneh M; Nagarkatti M; Nagarkatti PS
Blood; 1997 Sep; 90(5):1952-9. PubMed ID: 9292529
[TBL] [Abstract][Full Text] [Related]
38. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis.
Ungefroren H; Voss M; Jansen M; Roeder C; Henne-Bruns D; Kremer B; Kalthoff H
Cancer Res; 1998 Apr; 58(8):1741-9. PubMed ID: 9563493
[TBL] [Abstract][Full Text] [Related]
39. Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape.
Bernstorff WV; Glickman JN; Odze RD; Farraye FA; Joo HG; Goedegebuure PS; Eberlein TJ
Cancer; 2002 May; 94(10):2552-60. PubMed ID: 12173320
[TBL] [Abstract][Full Text] [Related]
40. Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and renal carcinomas.
Peduto Eberl L; Guillou L; Saraga E; Schröter M; French LE; Tschopp J; Juillerat-Jeanneret L
Int J Cancer; 1999 May; 81(5):772-8. PubMed ID: 10328232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
